JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaClaire, L. L.
Right arrow Articles by Popovic, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaClaire, L. L.
Right arrow Articles by Popovic, T.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2003, p. 393-396, Vol. 41, No. 1
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.1.393-396.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Identification of Haemophilus influenzae Serotypes by Standard Slide Agglutination Serotyping and PCR-Based Capsule Typing

Leslye L. LaClaire,1 Maria Lucia C. Tondella,1 David S. Beall,2 Corie A. Noble,3 Pratima L. Raghunathan,1 Nancy E. Rosenstein,1 Tanja Popovic,1* and the Active Bacterial Core Surveillance Team Members{dagger}

Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Disease, National Center for Infectious Disease, Centers for Disease Control and Prevention, Atlanta, Georgia 30333,1 Department of Biology, University of North Florida, Jacksonville, Florida 32224,2 VA Medical Center, Decatur, Georgia 300333

Received 30 July 2002/ Returned for modification 3 September 2002/ Accepted 7 October 2002

To resolve discrepancies in slide agglutination serotyping (SAST) results from state health departments and the Centers for Disease Control and Prevention (CDC), we characterized 141 of 751 invasive Haemophilus influenzae isolates that were identified in the United States from January 1998 to December 1999 through an active, laboratory-based, surveillance program coordinated by the CDC. We found discrepancies between the results of SAST performed at state health departments and those of PCR capsule typing performed at the CDC for 56 (40%) of the isolates characterized: 54 isolates that were identified as a particular serotype by SAST were shown to be unencapsulated by PCR, and two isolates that were reported as serotypes b and f were found to be serotypes f and e, respectively, by PCR. The laboratory error most likely to affect the perceived efficacy of the conjugate H. influenzae type b (Hib) vaccine was the misidentification of isolates as serotype b: of 40 isolates identified as serotype b by SAST, 27 (68%) did not contain the correlating capsule type genes. The frequency of errors fell substantially when standardized reagents and routine quality control of SAST were used during a study involving three laboratories. An overall 94% agreement between SAST and PCR results showed that slide agglutination could be a valid and reliable method for serotyping H. influenzae if the test was performed correctly, in accordance with standardized and recommended procedures. An ongoing prospective analysis of all H. influenzae surveillance isolates associated with invasive disease in children less than 5 years old will provide more accurate national figures for the burden of invasive disease caused by Hib and other H. influenzae serotypes.

* Corresponding author. Mailing address: Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Disease, National Center for Infectious Disease, Centers for Disease Control and Prevention, Atlanta, GA 30333. Phone: (404) 639-1730. Fax: (404) 639-3172. E-mail: txp1{at}cdc.gov.

{dagger} Principal investigators of the Active Bacterial Core Surveillance Team are as follows: A. Reingold (California Emerging Infections Program, Berkeley), J. Hadler (Connecticut Emering Infections Program, Hartford), L. Garrison (Maryland State Department of Health and Mental Hygiene, Baltimore), R. Lynfield (Minnesota Emerging Infections Program, Minneapolis), D. Morse (New York State Department of Health, Albany), P. Cieslak (Oregon Emerging Infections Program, Portland), and A. Craig (Tennessee Department of Public Health, Nashville).

Journal of Clinical Microbiology, January 2003, p. 393-396, Vol. 41, No. 1
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.1.393-396.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.